group therapy formats that may have influenced moderator analyses;[51; 52] and inferred values from other placebo-controlled trials for comparison conditions.[52] Additionally, prior meta-analyses did not examine treatment response (i.e., when a patient exhibits a clinically meaningful reduction in obsessive-compulsive severity) and symptoms/diagnostic remission (i.e., when a patient no longer meets syndromal criteria and/or has no more than minimal symptoms),[54; 55] which are two clinically meaningful metrics that are informative to treatment providers.[35; 47–52]
